Compare BAP & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAP | WST |
|---|---|---|
| Founded | 1889 | 1923 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 20.2B |
| IPO Year | 1995 | N/A |
| Metric | BAP | WST |
|---|---|---|
| Price | $291.14 | $274.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $260.17 | ★ $345.75 |
| AVG Volume (30 Days) | 317.2K | ★ 691.8K |
| Earning Date | 02-12-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.78% | 0.32% |
| EPS Growth | ★ 24.08 | 0.17 |
| EPS | ★ 23.44 | 6.75 |
| Revenue | ★ $5,896,627,147.00 | $3,017,900,000.00 |
| Revenue This Year | $23.30 | $7.01 |
| Revenue Next Year | $8.99 | $6.20 |
| P/E Ratio | ★ $12.44 | $40.63 |
| Revenue Growth | ★ 19.24 | 4.92 |
| 52 Week Low | $165.51 | $187.43 |
| 52 Week High | $292.00 | $348.90 |
| Indicator | BAP | WST |
|---|---|---|
| Relative Strength Index (RSI) | 69.13 | 51.83 |
| Support Level | $272.00 | $264.92 |
| Resistance Level | $293.00 | $279.01 |
| Average True Range (ATR) | 6.12 | 6.69 |
| MACD | 1.27 | 0.60 |
| Stochastic Oscillator | 94.41 | 61.67 |
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.